Faulty cytoskeleton impairs immune cells
(Vienna, July 25, 2018) In order to move, a body needs a strong scaffold. This is not only true on a macroscopic level, where animals rely on skeletons to support their muscles. It is also true on a cellular level: the cytoskeleton composed of actin filaments is crucial for every active movement of a cell. By rearranging these filaments, cells can stretch and wander in every direction, squeeze into the smallest gaps or wrap themselves around an object. Those processes are particularly important for the cells of the immune system, which are the most motile cells of the human body in order to fight against infectious agents. Defects of the cytoskeleton thus can have detrimental effects on the immune response and thereby on the ability of the organism to control infections.
In their most recent study, scientists from the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD) and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in cooperation with the University of Toulouse III, and INSERM, found that a rare genetic defect, characterized by a malfunctioning of the immune system, affects the ability of lymphocytes – the most important cells of the adaptive immunity – to rearrange their actin cytoskeleton. The study, published in the Journal of Allergy and Clinical Immunology (DOI: 10.1016/j.jaci.2018.04.023) was conducted in collaboration with clinicians from Izmir and Ankara and specialists of lymphocyte biology from the University of Vienna and the University of Rotterdam.
The gene defect was found in six patients who presented with severe infections of the lung, skin and oral mucosa. Genetic analyses of their genomes revealed mutations in a gene for a protein called WDR1, an important factor for the turn-over of actin filaments and thereby the dynamic remodeling of the cytoskeleton. It was recently shown that the innate arm of the immune system is affected by WDR1 mutations – the impact on cells of the adaptive immunity, however, was hitherto unknown. Through a series of extensive analyses, the researchers found that WDR1 deficiency leads to aberrant T-cell activation and B-cell development.
"We were able to show that T lymphocytes, although they appeared to develop normally in the patients, accumulated atypical actin structures. However, even more severe were the observed abnormalities in B lymphocytes" says Laurène Pfajfer, PhD student at LBI-RUD and shared first author of the study.
"Only few B cells were observed in the blood, and their progenitors in the bone marrow were also rare", Visiting Key Researcher at LBI-RUD and shared senior author Loïc Dupré, specifies. "And the few B cells we found showed a whole range of abnormalities, including reduced clonal diversity, abnormal spreading and increased apoptosis upon B-cell receptor stimulation".
"Our report expands the phenotypic spectrum of WDR1 deficiency, which comprises marked defects of both innate and adaptive immunity and illustrates the tight connection between immune system and uncontrolled inflammation which results in disease," summarizes Kaan Boztug, Director of LBI-RUD and shared senior author. "The results allowed us to gain new insights into the key role of actin cytoskeletal dynamics in supporting immune cell function. This study is another example for the value of research on rare diseases – not only for the few affected patients, but for a more global and fundamental understanding of human biology. Furthermore the elucidation of the fine mechanisms leading to such diseases provides unique insights for the development of precision medicine.
The study "Mutations affecting the actin regulator WD repeat-containing protein 1 lead to aberrant lymphoid immunity" was published in the Journal of Allergy and Clinical Immunology. DOI: 10.1016/j.jaci.2018.04.023
Authors: Laurène Pfajfer*, Nina K. Mair*, Raúl Jiménez-Heredia, Ferah Genel, Nesrin Gulez, Ömür Ardeniz, Birgit Hoeger, Sevgi Köstel Bal, MD, Christoph Madritsch, Artem Kalinichenko, Rico Chandra Ardy, Bengü Gerçeker, Javier Rey-Barroso, Hanna Ijspeert, Stuart G. Tangye, Ingrid Simonitsch-Klupp, Johannes B. Huppa, Mirjam van der Burg, Loïc Dupré*, and Kaan Boztug* (*equal contribution).
The study was funded by the Vienna Science and Technology Fund, the Austrian Science Fund, the French National Agency for Research, a ZonMW Vidi grant and grants from the National Health and Medical Research Council of Australia.
Kaan Boztug studied human medicine in Düsseldorf, Freiburg and London, after which he graduated with Ian Campbell at the Scripps Research Institute (La Jolla, US). He completed his clinical training and postgraduate research with Christoph Klein at Hannover Medical School prior to his first appointment as an independent group leader in 2011 at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences. Since 2011, he holds a dual appointment as Associate Professor at the Department of Paediatrics and Adolescent Medicine at the Medical University of Vienna. Since 2016, Kaan Boztug is director of the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases. He is furthermore director of the CeRUD Vienna Center for Rare and Undiagnosed Diseases as well as the Jeffrey Modell Diagnostic and Research Center Vienna at the Medical University of Vienna and the St. Anna Childrens' Hospital.
The mission of CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences is to achieve maximum scientific innovation in molecular medicine to improve healthcare. At CeMM, an international and creative team of scientists and medical doctors pursues free-minded basic life science research in a large and vibrant hospital environment of outstanding medical tradition and practice. CeMM's research is based on post-genomic technologies and focuses on societally important diseases, such as immune disorders and infections, cancer and metabolic disorders. CeMM operates in a unique mode of super-cooperation, connecting biology with medicine, experiments with computation, discovery with translation, and science with society and the arts. The goal of CeMM is to pioneer the science that nurtures the precise, personalized, predictive and preventive medicine of the future. CeMM trains a modern blend of biomedical scientists and is located at the campus of the General Hospital and the Medical University of Vienna.
The Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD) was launched by the Ludwig Boltzmann Gesellschaft in April 2016 together with its partner institutions including the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, the Medical University of Vienna and the Children's Cancer Research Institute and the St Anna Children's Hospital Vienna. Its research remit is the thorough analysis of rare diseases of the hematopoietic system, the immune system and the nervous system – as such not only dedicated to provide research for the development of personalized therapeutics for affected patients, but with similar efforts dedicated to unravel novel insights into human biology. Benefitting from full access to the infrastructure of its partner institutions, LBI-RUD has established a coordinated research programme, integrating and considering scientific, sociologic, ethical and economical aspects of rare diseases.
For further information please contact
Mag. Wolfgang Däuble
Media Relations Manager
Research Center for Molecular Medicine
of the Austrian Academy of Sciences
Lazarettgasse 14, AKH BT 25.3
1090 Vienna, Austria
Phone +43-1/40160-70 057
Fax +43-1/40160-970 000
<h4>Related Journal Article</h4>http://dx.doi.org/10.1016/j.jaci.2018.04.023